Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.

Sabine Tejpar; Ilhan Celik; Michael Schlichting; Ute Sartorius; Carsten Bokemeyer; Van Cutsem Eric

Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.

Standard

Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. / Tejpar, Sabine; Celik, Ilhan; Schlichting, Michael; Sartorius, Ute; Bokemeyer, Carsten; Eric, Van Cutsem.

In: J CLIN ONCOL, Vol. 30, No. 29, 29, 2012, p. 3570-3577.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Tejpar, S, Celik, I, Schlichting, M, Sartorius, U, Bokemeyer, C & Eric, VC 2012, 'Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.', J CLIN ONCOL, vol. 30, no. 29, 29, pp. 3570-3577. <http://www.ncbi.nlm.nih.gov/pubmed/22734028?dopt=Citation>

APA

Tejpar, S., Celik, I., Schlichting, M., Sartorius, U., Bokemeyer, C., & Eric, V. C. (2012). Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J CLIN ONCOL, 30(29), 3570-3577. [29]. http://www.ncbi.nlm.nih.gov/pubmed/22734028?dopt=Citation

Vancouver

Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Eric VC. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J CLIN ONCOL. 2012;30(29):3570-3577. 29.

Bibtex

@article{6609a906a585480fb2f28267276888fe,

title = "Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.",

abstract = "We investigated in the first-line setting our previous finding that patients with chemorefractory KRAS G13D-mutated metastatic colorectal cancer (mCRC) benefit from cetuximab treatment.",

keywords = "Adult, Humans, Male, Aged, Female, Middle Aged, Aged, 80 and over, Young Adult, Multivariate Analysis, Treatment Outcome, Risk Assessment, Survival Analysis, Follow-Up Studies, Disease-Free Survival, Proportional Hazards Models, Mutation, Gene Expression Regulation, Neoplastic, Neoplasm Staging, Neoplasm Metastasis, Likelihood Functions, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, Antibodies, Monoclonal/*therapeutic use, Proto-Oncogene Proteins/*genetics, ras Proteins/*genetics, Neoplasm Invasiveness/pathology, Colorectal Neoplasms/*drug therapy/*genetics/mortality/pathology, Adult, Humans, Male, Aged, Female, Middle Aged, Aged, 80 and over, Young Adult, Multivariate Analysis, Treatment Outcome, Risk Assessment, Survival Analysis, Follow-Up Studies, Disease-Free Survival, Proportional Hazards Models, Mutation, Gene Expression Regulation, Neoplastic, Neoplasm Staging, Neoplasm Metastasis, Likelihood Functions, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, Antibodies, Monoclonal/*therapeutic use, Proto-Oncogene Proteins/*genetics, ras Proteins/*genetics, Neoplasm Invasiveness/pathology, Colorectal Neoplasms/*drug therapy/*genetics/mortality/pathology",

author = "Sabine Tejpar and Ilhan Celik and Michael Schlichting and Ute Sartorius and Carsten Bokemeyer and Eric, {Van Cutsem}",

year = "2012",

language = "English",

volume = "30",

pages = "3570--3577",

journal = "J CLIN ONCOL",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "29",

}

RIS

TY - JOUR

T1 - Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.

AU - Tejpar, Sabine

AU - Celik, Ilhan

AU - Schlichting, Michael

AU - Sartorius, Ute

AU - Bokemeyer, Carsten

AU - Eric, Van Cutsem

PY - 2012

Y1 - 2012

N2 - We investigated in the first-line setting our previous finding that patients with chemorefractory KRAS G13D-mutated metastatic colorectal cancer (mCRC) benefit from cetuximab treatment.

AB - We investigated in the first-line setting our previous finding that patients with chemorefractory KRAS G13D-mutated metastatic colorectal cancer (mCRC) benefit from cetuximab treatment.

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Aged, 80 and over

KW - Young Adult

KW - Multivariate Analysis

KW - Treatment Outcome

KW - Risk Assessment

KW - Survival Analysis

KW - Follow-Up Studies

KW - Disease-Free Survival

KW - Proportional Hazards Models

KW - Mutation

KW - Gene Expression Regulation, Neoplastic

KW - Neoplasm Staging

KW - Neoplasm Metastasis

KW - Likelihood Functions

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Antibodies, Monoclonal/therapeutic use

KW - Proto-Oncogene Proteins/genetics

KW - ras Proteins/genetics

KW - Neoplasm Invasiveness/pathology

KW - Colorectal Neoplasms/drug therapy/genetics/mortality/pathology